天津招聘

Key Responsibilities:

o       Provide scientific support in biomarker discovery, development and translational science to preclinical projects and clinical trials.

o       Collaborate with preclinical and drug discovery scientists to design and execute translational research to discover biomarkers associated with mechanism of action, drug response /resistance, and identify rational combinations

o       Pro-active literature searching and understanding of the disease mechanism is required so that it is possible to develop working hypotheses to on-going translational studies.

o       Work efficiently in a multi-task environment, deliver hands-on work according to priorities and timelines.

o       Manage and coordinate the research work in CROs, ensure the high quality data delivered.

o       Keep updated with advance of new techniques, and leverage the external and internal platforms in biomarker studies.

Qualifications

o       PhD or Master candidates trained in molecular biology, immunology, medicine or a related field. Master candidates are required with >3 years of industry experience in pre-clinical drug discovery or translational research, preferably in a pharmaceutical setting or other relevant healthcare industry.

o       Experience of leading biomarker platforms such as NGS, molecular pathology, multiplex liquid assays and handling human biological samples is optional.

o       Experience of quantitatively image analysis or NGS data analysis is preferred.

o       The ideal candidate would also have a working knowledge of the challenges and experimental systems linked to drug discovery or diagnostic/biomarker research

o       Experience working with global and regional partners (internal and external) is highly preferred.

o       Demonstrated ability to work in a team oriented environment.

o       Good written and oral communication skill in both English and Chinese

    复宏汉霖（*******）是一家国际化的创新生物制药公司，旨在为全球患者提供质高价优的创新生物药，产品覆盖肿瘤、自身免疫性疾病等领域。自2010年成立以来，公司以全球联动、整合创新为产品开发理念，在中国上海、中国台北和美国加州均设有研发中心，具备了协同增效的突出优势。复宏汉霖主要的产品开发策略是仿创结合，从生物类似药起步，逐步开发创新型单抗产品，结合自主开发的抗PD-1和PD-L1单抗，在国内率先推出免疫联合疗法，前瞻性布局了一个多元化、创新单抗及肿瘤免疫联合疗法管线，打造出研究、开发、商业化生产的综合性生物医药全产业链平台。

    截至目前，复宏汉霖已有1个产品成功上市，2个产品获得中国新药上市申请受理，1个产品获得欧盟营销授权申请受理，10个产品、8个联合治疗方案在全球范围内开展20多项临床试验。其中，公司首款重磅产品汉利康？（利妥昔单抗注射液）于2019年2月获国家药监局新药上市注册批准，成为中国***获批上市的生物类似药。HLX03（阿达木单抗注射液）与HLX02（注射用曲妥珠单抗）已获国家药监局新药上市申请受理，现已纳入优先审评程序。HLX02相继在中国大陆、乌克兰、欧盟波兰和菲律宾全面启动国际多中心3期临床试验，成为国内***开展国际多中心3期临床研究的生物类似药，并于2019年6月获欧洲药品管理局营销授权申请受理。此外，公司已陆续就HLX10（抗PD-1单抗）与自有产品HLX04（贝伐珠单抗生物类似药）、HLX07（抗EGFR单抗）以及化疗联用开展多项肿瘤免疫联合疗法，在全球范围内开展多个临床研究。